Vision Systems bidding war continues
This article was originally published in The Gray Sheet
Executive Summary
Bidding competition for anatomical pathology instrument maker Vision Systems could gain a third contender in Danaher. The diversified manufacturer of microscopic imaging, measurement and analysis tools is considering making an offer for Vision after acknowledging preliminary discussions Sept. 26. Ventana offered $346 mil. for the firm Aug. 13, after which Cytyc proposed a $374 mil. deal Sept. 13. On Sept. 29, Cytyc increased its bid to $517 mil., to "underscore" its "commitment" to completing a transaction in the wake of "increased interest from potential acquirors." Ventana has acquired a 10.2% stake in Vision Systems through open market purchases of 22 mil. shares. Meanwhile, Cytyc has "commitments for 13.9%" of Vision's fully diluted shares (1"The Gray Sheet" Sept. 18, 2006, p. 6)...
You may also be interested in...
Vision Systems warms to Cytyc offer
Histology instrument maker Vision Systems formally terminates planned $346 mil. merger deal with Ventana Oct. 4 as it continues to weigh a rival $517 mil. acquisition bid from Cytyc. On Sept. 29, cytology device manufacturer Cytyc sweetened its initial $374 mil. counter-offer to the Ventana deal in response to increased interest from potential acquirors (1"The Gray Sheet" Oct. 2, 2006, In Brief). At $2.42 per share (based on current exchange rates), the latest Cytyc proposal represents a roughly 87% premium over Vision's Aug. 11 closing price of $1.29 - the last close prior to Ventana's offer of $1.61 per share. Microscopic imaging system maker Danaher also is considering making an offer for Vision Systems, possibly in conjunction with Ventana...
Cytyc’s Higher Bid For Vision Systems Puts Ball Back In Ventana’s Court
Cytyc's proposed $374 mil. offer for cancer and infectious disease detection equipment maker Vision Systems Sept. 13 could start a bidding war for the Australian company
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.